Current Therapeutic Strategies and Perspectives for Neuroprotection in Parkinson's Disease. 2020

Mohan K Ghanta, and P Elango, and Bhaskar L V K S
Department of Pharmacology, Sri Ramachandra Medical College and Research Institute, Sri Ramachandra Institute of Higher Education and Research (DU), Porur, Chennai-600116, Tamil Nadu, India.

Parkinson's disease is a progressive neurodegenerative disorder of dopaminergic striatal neurons in basal ganglia. Treatment of Parkinson's disease (PD) through dopamine replacement strategies may provide improvement in early stages and this treatment response is related to dopaminergic neuronal mass which decreases in advanced stages. This treatment failure was revealed by many studies and levodopa treatment became ineffective or toxic in chronic stages of PD. Early diagnosis and neuroprotective agents may be a suitable approach for the treatment of PD. The essentials required for early diagnosis are biomarkers. Characterising the striatal neurons, understanding the status of dopaminergic pathways in different PD stages may reveal the effects of the drugs used in the treatment. This review updates on characterisation of striatal neurons, electrophysiology of dopaminergic pathways in PD, biomarkers of PD, approaches for success of neuroprotective agents in clinical trials. The literature was collected from the articles in database of PubMed, MedLine and other available literature resources.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000066829 Neuroprotection The physiological processes and techniques used by the body to prevent neuronal injury and degeneration in the central nervous system following acute disorders or as a result of chronic neurodegenerative diseases. Neural Protection,Neuron Protection,Neuronal Protection,Protection, Neural,Protection, Neuron,Protection, Neuronal
D059290 Dopaminergic Neurons Neurons whose primary neurotransmitter is DOPAMINE. Dopamine Neurons,Dopamine Neuron,Dopaminergic Neuron,Neuron, Dopamine,Neuron, Dopaminergic,Neurons, Dopamine,Neurons, Dopaminergic
D018696 Neuroprotective Agents Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. Neuroprotectant,Neuroprotective Agent,Neuroprotective Drug,Neuroprotectants,Neuroprotective Drugs,Neuroprotective Effect,Neuroprotective Effects,Agent, Neuroprotective,Agents, Neuroprotective,Drug, Neuroprotective,Drugs, Neuroprotective,Effect, Neuroprotective,Effects, Neuroprotective

Related Publications

Mohan K Ghanta, and P Elango, and Bhaskar L V K S
March 1997, Experimental neurology,
Mohan K Ghanta, and P Elango, and Bhaskar L V K S
January 2009, Current pharmaceutical design,
Mohan K Ghanta, and P Elango, and Bhaskar L V K S
January 2010, Neuro-degenerative diseases,
Mohan K Ghanta, and P Elango, and Bhaskar L V K S
June 2016, International journal of molecular sciences,
Mohan K Ghanta, and P Elango, and Bhaskar L V K S
April 2005, La Revue du praticien,
Mohan K Ghanta, and P Elango, and Bhaskar L V K S
January 2021, Oxidative medicine and cellular longevity,
Mohan K Ghanta, and P Elango, and Bhaskar L V K S
January 1993, European neurology,
Mohan K Ghanta, and P Elango, and Bhaskar L V K S
December 2011, Fortschritte der Neurologie-Psychiatrie,
Mohan K Ghanta, and P Elango, and Bhaskar L V K S
May 1992, Annals of the New York Academy of Sciences,
Mohan K Ghanta, and P Elango, and Bhaskar L V K S
August 2018, Current opinion in neurology,
Copied contents to your clipboard!